GSK’s Mepolizumab Panel Review May Hinge On Eosinophil Utility In Patient Selection

With a high regulatory bar for safety and efficacy for new asthma drugs and a skeptical payer base, the significance of and effect on eosinophil counts will be a crucial consideration for the severe asthma candidate.